MK-3697
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


MK-3697
Description:
MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM. IC50 value: 0.95 nM (Ki) Target: Orexin 2 receptor antagonist MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. Herein we report additional SAR studies within the “triaryl” amide 2-SORA series focused on improvements in compound stability in acidic media and time-dependent inhibition of CYP3A4. MK-3697 has improved stability and TDI profiles as well as excellent sleep efficacy across species.UNSPSC:
12352005Hazard Statement:
H302-H315-H319-H335Target:
Orexin Receptor (OX Receptor)Type:
Reference compoundRelated Pathways:
GPCR/G Protein; Neuronal SignalingApplications:
Neuroscience-NeuromodulationField of Research:
Neurological Disease; EndocrinologyAssay Protocol:
https://www.medchemexpress.com/MK-3697.htmlPurity:
98.83Solubility:
DMSO : 22.5 mg/mL (ultrasonic; warming)Smiles:
O=C(C1=CC(C2=CC(C)=CN=C2)=NC=C1C3=NC=CS3)NCC4=NC(OC)=C(OC)C=C4Molecular Formula:
C23H21N5O3SMolecular Weight:
447.51Precautions:
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501References & Citations:
[1]Anthony J. Roecker, et al. Discovery of MK-3697: A Selective Orexin 2 Receptor Antagonist (2-SORA) for the Treatment of Insomnia. Bioorganic & Medicinal Chemistry Letters Available online 26 August 2014Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
Phase 2Isoform:
OX2 ReceptorCAS Number:
1224846-01-8
